Source: Eur Respir J 2011; 37: 1332-1339
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Rello J., Ulldemolins M., Lisboa T., Koulenti D., Mañez R., Martin-Loeches I., De Waele J.J., Putensen C., Guven M., Deja M., Diaz E.. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J 2011; 37: 1332-1339

Member's Comments

No comment yet.

Related content which might interest you: Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Optimising the duration of antibiotic therapy for ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 40-44 Year: 2007 Impact of guidelines on HAP and VAP outcomes Source: Eur Respir Mon 2011; 53: 66-73 Year: 2011 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Appropriateness and delay to initiate therapy in ventilator-associated pneumonia Source: Eur Respir J 2006; 27: 158-164 Year: 2006 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Source: Eur Respir J 2002; 20: 432-439 Year: 2002 VAP: approach to therapy Source: Eur Respir Mon 2011; 53: 36-47 Year: 2011 Challenges in the management of hospital-acquired pneumonia including ventilator-associated pneumonia Source: ERS Course 2018 - Respiratory Infections Year: 2018 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients Source: Eur Respir J 2003; 22: 77S-83S Year: 2003 Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome Source: Eur Respir J 2008; 32: 892-901 Year: 2008 Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004 Hospital-acquired pneumonia: coverage and treatment adequacy of current guidelines Source: Eur Respir J 2003 Dec 01;22(6):876-882 Year: 2003 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 VAP prevention: pharmacological strategies Source: Eur Respir Mon 2011; 53: 74-82 Year: 2011 Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007